Date
Title
Date
12/12/24
Title
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Date
12/10/24
Title
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
Date
12/02/24
Title
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
11/25/24
Title
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Date
11/12/24
Title
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Date
11/01/24
Title
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
10/31/24
Title
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Date
10/23/24
Title
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
Date
10/16/24
Title
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress